TriangleHEALTH PROFESSIONAL · SOURCE READING
Topical imiquimod
Source: Vulvar Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Among women with high-grade VIN, substantial response rates and acceptable tolerability were reported for topical imiquimod 5%, an immune-response modifier with activity in human papillomavirus types 6- and 11-associated vulvar condylomata.
Evidence (imiquimod):
Three randomized placebo-controlled trials (including a total of 104 patients) with clinical response as the primary end points have been reported in either peer-reviewed-journals or in abstract format.[7];[4-6][Level of evidence B3] The results of these trials were summarized in a systematic review.[8]
Source links and citations
Three randomized placebo-controlled trials (including a total of 104 patients) with clinical response as the primary end points have been reported in either peer-reviewed-journals or in abstract format.[7];[4-6][Level of evidence B3] The results of these trials were summarized in a systematic review.[8]
At 5 to 6 months, the complete response rates in patients were 36 of 62 in the combined imiquimod arm versus 0 of 42 in the combined placebo arm, and the partial response rates were 18 of 62 in the combined imiquimod arm versus 1 of 42 in the combined placebo arm (relative risk, 11.95; 95% confidence interval, 3.21–44.51).
Three randomized placebo-controlled trials (including a total of 104 patients) with clinical response as the primary end points have been reported in either peer-reviewed-journals or in abstract format.[7];[4-6][Level of evidence B3] The results of these trials were summarized in a systematic review.[8]
In the only trial reporting progression to cancer at 12 months, there was no difference in progression rate, but the trial was severely underpowered because only 3 of the total 52 women developed invasive disease by 12 months.[6]
Source links and citations
Three randomized placebo-controlled trials (including a total of 104 patients) with clinical response as the primary end points have been reported in either peer-reviewed-journals or in abstract format.[7];[4-6][Level of evidence B3] The results of these trials were summarized in a systematic review.[8]
The only trial reporting quality of life [6] showed no difference between imiquimod and placebo.
Source links and citations
Three randomized placebo-controlled trials (including a total of 104 patients) with clinical response as the primary end points have been reported in either peer-reviewed-journals or in abstract format.[7];[4-6][Level of evidence B3] The results of these trials were summarized in a systematic review.[8]
Local side effects of imiquimod included pain, edema, erythema, and a single case of erosion. However, no patients had to discontinue treatment as a result of toxicity.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice